SCHEMBL25822288

SCHEMBL25822288

CNCCOc1cccc(OCCCC(C)=O)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.62
ALDH1A1 P00352 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
NSD2 O96028 1/20 0.60
MTNR1A P48039 2/20 0.55
MTNR1B P49286 2/20 0.55
HTR1B P28222 2/20 0.53
HTR1D P28221 1/20 0.53
LMNA P02545 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
CHRNB2 P17787 1/20 0.49
CHRNA4 P43681 1/20 0.49
POLB P06746 1/20 0.46
HPGD P15428 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
MAPK1 P28482 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8901248 0.88 KDM4E (0.62) KDM4EALDH1A1SMN1; SMN2NSD2MTNR1A
SCHEMBL25820387 0.87 KDM4E (0.60) KDM4EALDH1A1SMN1; SMN2NSD2MTNR1A
SCHEMBL18611549 0.86 KDM4E (0.59) KDM4EALDH1A1SMN1; SMN2NSD2MTNR1A
SCHEMBL18611546 0.84 KDM4E (0.51) KDM4EALDH1A1SMN1; SMN2NSD2MTNR1A
SCHEMBL25820408 0.84 KDM4E (0.58) KDM4EALDH1A1SMN1; SMN2NSD2MTNR1A
SCHEMBL13349920 0.83 PLA2G4B (0.56) LMNAL3MBTL1KMT2AMAPK1
SCHEMBL13881713 0.81 KDM4E (0.60) KDM4EALDH1A1SMN1; SMN2NSD2MTNR1A
SCHEMBL4569112 0.80 MTNR1A (0.53) KDM4EALDH1A1SMN1; SMN2NSD2MTNR1A
SCHEMBL13523837 0.80 SMN1; SMN2 (0.65) ALDH1A1SMN1; SMN2LMNAL3MBTL1POLB
SCHEMBL19291375 0.80 KDM4E (0.58) KDM4EALDH1A1SMN1; SMN2NSD2MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218549-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ACUCELA INC. 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218549-A1 ALKOXY COMPOUNDS FOR DISEASE TREATMENT ALDH1A2, CLN6, AGER KDM4E 2227/4885ALDH1A1 133/4885SMN1; SMN2 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.